Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The central dogma of molecular biology
- Protein folding
- Competition - folding, misfolding, aggregation
- The proteostasis network
- Gain of function disease
- Loss of function disease
- The transthyretin (TTR) amyloidoses
- The mechanism of protein aggregation
- Transthyretin (TTR)
- The mechanism by which TTR aggregates
- Ligand binding can stabilize tetramers
- A key human genetics observation
- TTR tetramer dissociation is rate-limiting
- Interallelic trans–suppression improves pathology
- Native state kinetic stabilization
- Tafamidis designed with X-ray crystallography
- Clinical trials
- NIS-LL neurological exam
- mBMI: modified body mass index
- Tafamidis therapy approved in EU for TTR-FAP
- Liver transplant: the only approach until 2011
- Portuguese experience with tafamidis
- Kinetic stabilizers extend lifespan in TTR
- Pfizer cardiomyopathy trial completed
- Repurposing diflunisal
- Pharmacologic support for the amyloid hypothesis
- Eye and CNS pathology emerging in patients
- PIB-PET transthyretin cerebral amyloid angiopathy
- The tafamidis development timeline
- Part 1: Conclusions
- Improving protein misfolding/aggregation diseases
- Sub-cellular proteostasis network regulation
- Protein folding vs. degradation in the ER
- The unfolded protein response (UPR)
- Arm-selective UPR transcriptional programs
- The ER proteostasis network pathways
- ATF6 activation reduces secretion of TTR mutant
- Screening strategy for discovering UPR activators
- ERSE-FLuc reporter small molecule activation
- Transcriptional program drives structure-activity
- ATF6 activation reduces secretion of mutant TTR
- Part 2: Conclusions
- Acknowledgments
Topics Covered
- Protein folding, misfolding, aggregation
- The proteostasis network and its regulation
- Gain and loss of function diseases
- The transthyretin (TTR) amyloidosis
- Kinetic stabilizers & clinical trial results
- Tafamidis & Diflunisal: evidence for the amyloid hypothesis
- Improving protein misfolding/aggregation diseases
- The unfolded protein response (UPR) and its arm-selective activators
- ATF6 activation & reduction of TTR mutant
- Clinical trials in amyloidosis with cardiac involvement
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kelly, J.W. (2018, December 31). Adapting proteostasis to ameliorate aggregation-associated amyloid diseases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/ROLG5239.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Jeffery W. Kelly has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Biochemistry
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Jeff Kelly from
the Scripps Research Institute and it's a privilege today to give a Henry Stewart talk.
Focused on adapting the biology and/or chemistry of
protein homeostasis to ameliorate diseases
where protein aggregation causes degenerative phenotypes.
0:19
Even the most experienced scientists sometimes catch themselves
thinking about translation as affording folded functional proteins.
0:30
But in fact, translation affords
an unordered ensemble of conformers that generally speaking,
have to fold in order to function,
and while protein folding can be spontaneous.
For the vast majority of human proteins,
protein folding is assisted in some cases catalyzed by the protein homeostasis network.
This is because of the reasons listed at the bottom of the slide in part.
That is, there are chemical processes like
peptidyl-prolyl amide bond isomerization and
disulfide bond formation that are simply too slow to support life,
and those processes must be catalyzed by enzymes.
1:14
Moreover, there's always a kinetic competition between protein folding,
protein misfolding, and concentration dependent protein aggregation.
And it's important that the biological components of the protein homeostasis network regulate
these competitive processes such that
sufficient function is maintained in the cell and in the extracellular space.
Hide